Keywords: chiron, 2nd-qtr, income, dips, sales, rise, acquisition
Chiron's 2nd-qtr income dips but sales rise
Article | 02 August 2004
Chiron's acquisition of PowderJect Pharmaceuticals last year(Marketletters passim) continued to bite into the US firm's earnings, with second-quarter pro ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
